Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age3 Years to 31 Years
• SexAll
• Healthy volunteersNo

You may be able to join if

• Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:
• Diffuse Large B-Cell Lymphoma
• Burkitt Lymphoma
• High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)
• Primary mediastinal B-cell lymphoma (PMBL)
• CD20+ B-lymphoblastic lymphoma
• Follicular lymphoma, Grade III
• Karnofsky ≥ 60% for patients > 16 years of age and
• Lansky ≥ 60 for patients ≤ 16 years of age.
• Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.
• Patients may not have received prior therapy with obinutuzumab (GA101)
• Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local palliative XRT (small port); > 6 months must have elapsed if prior craniospinal XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other substantial bone marrow radiation.
• Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.
• Adequate organ function.

You cannot join if

• Patients with newly diagnosed, previously untreated B-NHL.
• Known congenital or acquired immune deficiency.
• Prior solid organ transplantation.
• Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
• History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies
• Uncontrolled hepatitis B and/or C infection

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

obinutuzumab. A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells. NCI Drug Dictionary

Treatments listed in the registry

• Obinutuzumab (Drug): Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
• Liposomal ARA-C (Drug): Will be given intrathecally for both prophylaxis and treatment of CNS disease.
• Ifosfamide (Drug): Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
• Carboplatin (Drug): Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
• Etoposide (Drug): Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).

Non Randomized · Parallel · masking: None

Main goals

• Safety as assessed by adverse reactions and events (1 month)
• Response rate assessed following each treatment cycle for regression of tumor (3 months)

Planned enrollment: 25 (estimated).

• New York Medical College, Valhalla, New York

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT02393157
• NCI Drug Dictionary: C70741

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Oct 22, 2026. Public record; not medical advice.